BLCO – Bausch + Lomb Corporation
Bausch + Lomb CorporationBLCO
$17.36Name : Bausch + Lomb Corporation
Sector : Healthcare
Industry: Medical Instruments & Supplies
Mark. Cap: $6,113,567,232.00
EPSttm : -1.04
Bausch + Lomb Corporation
$17.36
0.46%$0.08Float Short %
3.48
Margin Of Safety %
Put/Call OI Ratio
0.16
EPS Next Q Diff
-0.04
EPS Last/This Y
EPS This/Next Y
0.25
Price
17.37
Target Price
20.92
Analyst Recom
2.38
Performance Q
-16.42
Relative Volume
1.45
Beta
0.47
Ticker: BLCO
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2024-12-19 | BLCO | 17.96 | 0.25 | 0.07 | 25004 |
| 2024-12-20 | BLCO | 17.98 | 0.23 | 0.50 | 25017 |
| 2024-12-23 | BLCO | 17.82 | 0.26 | 0.73 | 11373 |
| 2024-12-24 | BLCO | 17.86 | 0.28 | 0.16 | 11708 |
| 2024-12-26 | BLCO | 18.15 | 0.26 | 0.53 | 11753 |
| 2024-12-27 | BLCO | 17.98 | 0.26 | 0.20 | 11859 |
| 2024-12-30 | BLCO | 17.78 | 0.26 | 0.14 | 12542 |
| 2024-12-31 | BLCO | 18.07 | 0.25 | 0.16 | 13586 |
| 2025-01-02 | BLCO | 18.02 | 0.25 | 0.21 | 13838 |
| 2025-01-03 | BLCO | 17.75 | 0.25 | 0.00 | 14053 |
| 2025-01-06 | BLCO | 17.64 | 0.23 | 0.13 | 15058 |
| 2025-01-07 | BLCO | 17.88 | 0.22 | 0.04 | 15613 |
| 2025-01-08 | BLCO | 18.07 | 0.22 | 0.05 | 16007 |
| 2025-01-09 | BLCO | 18.08 | 0.22 | 0.04 | 16007 |
| 2025-01-10 | BLCO | 17.75 | 0.22 | 0.14 | 16177 |
| 2025-01-13 | BLCO | 17.39 | 0.21 | 0.00 | 16232 |
| 2025-01-14 | BLCO | 17.22 | 0.19 | 0.09 | 17852 |
| 2025-01-15 | BLCO | 17.27 | 0.19 | 0.03 | 17757 |
| 2025-01-16 | BLCO | 17.42 | 0.16 | 0.41 | 17708 |
| 2025-01-17 | BLCO | 17.37 | 0.16 | 2.55 | 18771 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2024-12-19 | BLCO | 17.95 | -1.3 | - | 0.60 |
| 2024-12-20 | BLCO | 18.01 | -1.3 | - | 0.60 |
| 2024-12-23 | BLCO | 17.83 | -1.3 | - | 0.60 |
| 2024-12-24 | BLCO | 17.86 | -1.3 | - | 0.60 |
| 2024-12-26 | BLCO | 18.14 | -1.3 | - | 0.60 |
| 2024-12-27 | BLCO | 17.99 | -1.3 | 206.1 | 0.60 |
| 2024-12-30 | BLCO | 17.78 | -1.3 | 202.2 | 0.60 |
| 2024-12-31 | BLCO | 18.07 | -1.3 | 210.8 | 0.60 |
| 2025-01-02 | BLCO | 18.00 | -1.3 | - | 0.60 |
| 2025-01-03 | BLCO | 17.75 | -1.3 | 205.8 | 0.60 |
| 2025-01-06 | BLCO | 17.64 | -1.3 | 205.0 | 0.60 |
| 2025-01-07 | BLCO | 17.89 | -1.3 | - | 0.60 |
| 2025-01-08 | BLCO | 18.08 | -1.3 | - | 0.60 |
| 2025-01-09 | BLCO | 18.08 | -1.3 | - | 0.60 |
| 2025-01-10 | BLCO | 17.78 | -1.3 | - | 0.60 |
| 2025-01-13 | BLCO | 17.39 | -1.3 | - | 0.60 |
| 2025-01-14 | BLCO | 17.24 | -1.3 | - | 0.60 |
| 2025-01-15 | BLCO | 17.27 | -1.3 | - | 0.60 |
| 2025-01-16 | BLCO | 17.42 | -1.3 | - | 0.60 |
| 2025-01-17 | BLCO | 17.37 | -1.3 | - | 0.60 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2024-12-19 | BLCO | 0.01 | -8.84 | 3.09 |
| 2024-12-20 | BLCO | 0.01 | -8.84 | 3.09 |
| 2024-12-23 | BLCO | 0.01 | -8.84 | 3.09 |
| 2024-12-24 | BLCO | 0.01 | -8.84 | 3.09 |
| 2024-12-26 | BLCO | 0.01 | -8.84 | 3.46 |
| 2024-12-27 | BLCO | 0.01 | -8.84 | 3.46 |
| 2024-12-30 | BLCO | 0.01 | -8.84 | 3.45 |
| 2024-12-31 | BLCO | 0.01 | -8.84 | 3.45 |
| 2025-01-02 | BLCO | 0.01 | -8.84 | 3.45 |
| 2025-01-03 | BLCO | 0.01 | -8.84 | 3.45 |
| 2025-01-06 | BLCO | 0.01 | -8.99 | 3.45 |
| 2025-01-07 | BLCO | 0.01 | -8.99 | 3.45 |
| 2025-01-08 | BLCO | 0.01 | -8.99 | 3.45 |
| 2025-01-09 | BLCO | 0.01 | -8.99 | 3.45 |
| 2025-01-10 | BLCO | 0.01 | -8.99 | 3.45 |
| 2025-01-13 | BLCO | 0.01 | -9.00 | 3.48 |
| 2025-01-14 | BLCO | 0.01 | -9.00 | 3.48 |
| 2025-01-15 | BLCO | 0.01 | -9.00 | 3.48 |
| 2025-01-16 | BLCO | 0.01 | -9.00 | 3.48 |
| 2025-01-17 | BLCO | 0.01 | -9.00 | 3.48 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.17
Avg. EPS Est. Current Quarter
0.24
Avg. EPS Est. Next Quarter
0.13
Insider Transactions
0.01
Institutional Transactions
-9
Beta
0.47
Average Sales Estimate Current Quarter
1258
Average Sales Estimate Next Quarter
1167
Fair Value
Quality Score
55
Growth Score
85
Sentiment Score
15
Actual DrawDown %
20.9
Max Drawdown 5-Year %
Target Price
20.92
P/E
Forward P/E
21.28
PEG
P/S
1.31
P/B
0.93
P/Free Cash Flow
EPS
-1.05
Average EPS Est. Cur. Y
0.6
EPS Next Y. (Est.)
0.84
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-7.86
Relative Volume
1.45
Return on Equity vs Sector %
-24.7
Return on Equity vs Industry %
-15.3
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.01
EBIT Estimation
Bausch + Lomb CorporationSector: Healthcare
Industry: Medical Instruments & Supplies
Employees: 13000
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. The company has collaboration agreement with City Therapeutics, Inc. to develop a Novel RNAi-Based treatment for geographic atrophy. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.
stock quote shares BLCO – Bausch + Lomb Corporation Stock Price stock today
news today BLCO – Bausch + Lomb Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch BLCO – Bausch + Lomb Corporation yahoo finance google finance
stock history BLCO – Bausch + Lomb Corporation invest stock market
stock prices BLCO premarket after hours
ticker BLCO fair value insiders trading